Acute exacerbation of CRS (Chronic Rhinosinusitis) is regarded as a serious airway disease. According to the World Health Organization (WHO) recommendations, it may be a risk factor for exposure to COVID-19 as well as for existing COVID-19 positive patients. Hence, companies in the acute exacerbation of CRS treatment market are increasing the availability of treatments and medicines to reduce morbidity and mortality of patients.
Manufacturers in the acute exacerbation of CRS treatment market are boosting their production capacities in intranasal corticosteroids that are considered as the gold standard for CRS in patients with coronavirus. Stakeholders are gaining awareness about reducing surgical treatments to the minimum. Treatment with biologics is being recommended with careful monitoring in non-infected patients and should be temporarily interrupted during COVID-19 infection.
To know the scope of our report Get a Sample on Acute Exacerbation of CRS Treatment Market
CRS with nasal polyps (CRSwNP) is a common and heterogeneous inflammatory disease of the upper respiratory tract. Despite the potential value of biomarker-based endotyping to provide guidance regarding optimal care and treatment choices for patients with CRSwNP, the current practice is largely not biomarker-based. This explains why the acute exacerbation of CRS treatment market is slated to register a CAGR of 4.6% from 2021 to 2031. Hence, companies are now increasing focus on biologics, especially for patients before considering initial surgery.
Patients with comorbid severe asthma and for whom surgery is less available are opting for biologics. Biologics are being recommended for use immediately following surgery in patients who have a history of nasal polyp recurrence within 12 months of a prior surgery.
Get a glimpse of the in-depth analysis through our Report Brochure
Severe asthma and acute exacerbation of CRS lead to frequent comorbidities, thus complicating the overall management of the disease. Biomarkers such as absolute eosinophil count in peripheral blood and fractional exhaled nitric oxide (FeNO) may be used as indicators of type 2 asthma endotypes and help predict response to biologic therapies.
There is data indicating that the presence of CRS is associated with worse outcomes in patients with asthma, more specifically with increased risk of frequent exacerbations. Hence, companies in the acute exacerbation of CRS treatment market are increasing their production capabilities in antibiotics, oral analgesics, and intranasal steroids, among other treatment options to improve patient outcomes.
Defining acute exacerbations of CRS with quantifiable clinical and immunologic metrics has remained a challenge due to the complex etiology of acute exacerbations and the inconsistency in endpoint reporting. Current recommendations for treatment of acute exacerbation of CRS continue to suggest blanket medical intervention, including short-course antibiotic treatment. Companies in the acute exacerbation of CRS treatment market are increasing R&D to improve methods for clinically defining the disease and its risk factors to facilitate individualized treatment.
Manufacturers in the acute exacerbation of CRS treatment market are boosting their output capacities in first-line antibiotic therapies such as amoxicillin, with or without clavulanate to improve patient quality of life.
Expanding operations in future? To get the perfect launch ask for a custom report
Analysts’ Viewpoint
Healthcare providers are closely monitoring the COVID-19 situation and have recommended aligning any diagnostic and treatment operations with guidance from the WHO and Centers for Disease Control and Prevention (CDC). The acute exacerbation of CRS treatment market is expected to reach US$ 7.06 Bn by 2031. Though available biological agents have therapeutic effects for patients with asthma and CRS, the improvement of nasal symptoms is less evident, despite reaching satisfactory asthma control. Hence, companies should improve their knowledge in potential therapeutic agents and increase the ability of biological agents to equally reach different tissues in order to improve patient outcomes.
Acute Exacerbation of CRS Treatment Market – Segmentation
TMR’s study on the global acute exacerbation of CRS treatment market includes information divided into four segments: treatment, route of administration, distribution channel, infection type, and region.
| Treatment |
|
| Route of Administration |
|
| Distribution Channel |
|
| Infection Type |
|
| Region |
|
Changing industry trends and other crucial market dynamics associated with these segments of the global acute exacerbation of CRS treatment market have been discussed in detail.
Acute exacerbation of CRS treatment market to reach valuation of US$ 7.06 bn by 2031
Acute exacerbation of CRS treatment market is projected to expand at a CAGR of 4.6% from 2021 to 2031
Acute exacerbation of CRS treatment market is driven by increase in instances of rhinosinusitis
North America dominated the global acute exacerbation of CRS treatment market and the trend is anticipated to continue during the forecast period
Key players in the global acute exacerbation of CRS treatment market include Sun Pharmaceutical Industries, Inc., Pfizer Inc., Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Fresenius Kabi USA, LLC
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Acute Exacerbation of CRS Treatment Market
4. Market Overview
4.1. Introduction & Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Global Acute Exacerbation of CRS Treatment Market Analysis and Forecast, 2017–2031
5. Market Outlook
5.1. Clinical Trials & Regulatory Approvals Analysis
5.2. List of Brand / Product Approved
5.3. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
5.4. Technological Advancements
5.5. Disease Prevalence & Incidence
6. Global Acute Exacerbation of CRS Treatment Market Analysis and Forecast, by Treatment
6.1. Introduction & Definition
6.2. Global Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
6.2.1. Acute Exacerbation of CRS
6.2.1.1. Antibiotics
6.2.1.2. Leukotriene Inhibitors
6.2.1.3. Antihistamines
6.2.1.4. Mucolytics
6.2.1.5. Decongestants
6.2.1.6. Nasal Saline Irrigation
6.2.1.7. Oral Corticosteroids
6.2.1.8. Endoscopic sinus surgery
6.2.1.9. Others
6.3. Global Acute Exacerbation of CRS Treatment Market Attractiveness Analysis, by Route of Administration
7. Global Acute Exacerbation of CRS Treatment Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Global Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Route of Administration2017–2031
7.2.1. Acute Exacerbation of CRS
7.2.1.1. Topical
7.2.1.2. Nasal
7.2.1.3. Oral
7.2.1.4. Injectable
7.3. Global Acute Exacerbation of CRS Treatment Market Attractiveness Analysis, by Route of Administration
8. Global Acute Exacerbation of CRS Treatment Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Global Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
8.2.1. Acute Exacerbation of CRS
8.2.1.1. Online Pharmacies
8.2.1.2. Retail Pharmacies
8.2.1.3. Hospital Pharmacies
8.3. Global Acute Exacerbation of CRS Treatment Market Attractiveness Analysis, by Distribution Channel
9. Global Acute Exacerbation of CRS Treatment Market Analysis and Forecast, by Infection Type
9.1. Introduction & Definition
9.2. Global Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
9.2.1. Acute Exacerbation of CRS
9.2.1.1. Staphylococcus Species
9.2.1.2. Others
9.3. Global Acute Exacerbation of CRS Treatment Market Attractiveness Analysis, by Infection Type
10. Global Acute Exacerbation of CRS Treatment Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Global Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Global Acute Exacerbation of CRS Treatment Market Attractiveness Analysis, by Region
11. North America Acute Exacerbation of CRS Treatment Market Analysis and Forecast
11.1. Introduction
11.2. North America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
11.2.1. Acute Exacerbation of CRS
11.2.1.1. Antibiotics
11.2.1.2. Leukotriene Inhibitors
11.2.1.3. Antihistamines
11.2.1.4. Mucolytics
11.2.1.5. Decongestants
11.2.1.6. Nasal Saline Irrigation
11.2.1.7. Oral Corticosteroids
11.2.1.8. Endoscopic sinus surgery
11.2.1.9. Others
11.3. North America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
11.3.1. Acute Exacerbation of CRS
11.3.1.1. Topical
11.3.1.2. Nasal
11.3.1.3. Oral
11.3.1.4. Injectable
11.4. North America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
11.4.1. Acute Exacerbation of CRS
11.4.1.1. Online Pharmacies
11.4.1.2. Retail Pharmacies
11.4.1.3. Hospital Pharmacies
11.5. North America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
11.5.1. Acute Exacerbation of CRS
11.5.1.1. Staphylococcus Species
11.5.1.2. Others
11.6. North America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. North America Acute Exacerbation of CRS Treatment Market Attractiveness Analysis
11.7.1. By Treatment
11.7.2. By Route of Administration
11.7.3. By Distribution Channel
11.7.4. Infection Type
11.7.5. By Country
12. Europe Acute Exacerbation of CRS Treatment Market Analysis and Forecast
12.1. Introduction
12.2. Europe Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
12.2.1. Acute Exacerbation of CRS
12.2.1.1. Antibiotics
12.2.1.2. Leukotriene Inhibitors
12.2.1.3. Antihistamines
12.2.1.4. Mucolytics
12.2.1.5. Decongestants
12.2.1.6. Nasal Saline Irrigation
12.2.1.7. Oral Corticosteroids
12.2.1.8. Endoscopic sinus surgery
12.2.1.9. Others
12.3. Europe Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
12.3.1. Acute Exacerbation of CRS
12.3.1.1. Topical
12.3.1.2. Nasal
12.3.1.3. Oral
12.3.1.4. Injectable
12.4. Europe Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
12.4.1. Acute Exacerbation of CRS
12.4.1.1. Staphylococcus Species
12.4.1.2. Others
12.5. Europe Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
12.5.1. Germany
12.5.2. U.K.
12.5.3. France
12.5.4. Spain
12.5.5. Italy
12.5.6. Rest of Europe
12.6. Europe Acute Exacerbation of CRS Treatment Market Attractiveness Analysis
12.6.1. By Treatment
12.6.2. By Route of Administration
12.6.3. By Distribution Channel
12.6.4. By Infection Type
12.6.5. By Country/Sub-region
13. Asia Pacific Acute Exacerbation of CRS Treatment Market Analysis and Forecast
13.1. Introduction
13.2. Asia Pacific Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
13.2.1. Acute Exacerbation of CRS
13.2.1.1. Antibiotics
13.2.1.2. Leukotriene Inhibitors
13.2.1.3. Antihistamines
13.2.1.4. Mucolytics
13.2.1.5. Decongestants
13.2.1.6. Nasal Saline Irrigation
13.2.1.7. Oral Corticosteroids
13.2.1.8. Endoscopic sinus surgery
13.2.1.9. Others
13.3. Asia Pacific Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
13.3.1. Acute Exacerbation of CRS
13.3.1.1. Topical
13.3.1.2. Nasal
13.3.1.3. Oral
13.3.1.4. Injectable
13.4. Asia Pacific Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
13.4.1. Acute Exacerbation of CRS
13.4.1.1. Online Pharmacies
13.4.1.2. Retail Pharmacies
13.4.1.3. Hospital Pharmacies
13.5. Asia Pacific Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
13.5.1. China
13.5.2. Japan
13.5.3. India
13.5.4. Australia & New Zealand
13.5.5. Rest of Asia Pacific
13.6. Asia Pacific Acute Exacerbation of CRS Treatment Market Attractiveness Analysis
13.6.1. By Treatment
13.6.2. By Route of Administration
13.6.3. By Distribution Channel
13.6.4. Infection Type
13.6.5. By Country/Sub-region
14. Latin America Acute Exacerbation of CRS Treatment Market Analysis and Forecast
14.1. Introduction
14.2. Latin America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
14.2.1. Acute Exacerbation of CRS
14.2.1.1. Antibiotics
14.2.1.2. Leukotriene Inhibitors
14.2.1.3. Antihistamines
14.2.1.4. Mucolytics
14.2.1.5. Decongestants
14.2.1.6. Nasal Saline Irrigation
14.2.1.7. Oral Corticosteroids
14.2.1.8. Endoscopic sinus surgery
14.2.1.9. Others
14.3. Latin America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
14.3.1. Acute Exacerbation of CRS
14.3.1.1. Topical
14.3.1.2. Nasal
14.3.1.3. Oral
14.3.1.4. Injectable
14.4. Latin America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
14.4.1. Acute Exacerbation of CRS
14.4.1.1. Online Pharmacies
14.4.1.2. Retail Pharmacies
14.4.1.3. Hospital Pharmacies
14.5. Latin America Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
14.5.1. Brazil
14.5.2. Mexico
14.5.3. Rest of Latin America
14.6. Latin America Acute Exacerbation of CRS Treatment Market Attractiveness Analysis
14.6.1. By Treatment
14.6.2. By Route of Administration
14.6.3. By Distribution Channel
14.6.4. Infection Type
14.6.5. By Country/Sub-region
15. Middle East & Africa Acute Exacerbation of CRS Treatment Market Analysis and Forecast
15.1. Introduction
15.2. Middle East & Africa Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
15.2.1. Acute Exacerbation of CRS
15.2.1.1. Antibiotics
15.2.1.2. Leukotriene Inhibitors
15.2.1.3. Antihistamines
15.2.1.4. Mucolytics
15.2.1.5. Decongestants
15.2.1.6. Nasal Saline Irrigation
15.2.1.7. Oral Corticosteroids
15.2.1.8. Endoscopic sinus surgery
15.2.1.9. Others
15.3. Middle East & Africa Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
15.3.1. Acute Exacerbation of CRS
15.3.1.1. Topical
15.3.1.2. Nasal
15.3.1.3. Oral
15.3.1.4. Injectable
15.4. Middle East & Africa Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
15.4.1. Acute Exacerbation of CRS
15.4.1.1. Online Pharmacies
15.4.1.2. Retail Pharmacies
15.4.1.3. Hospital Pharmacies
15.5. Middle East & Africa Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
15.5.1. Acute Exacerbation of CRS
15.5.1.1. Staphylococcus Species
15.5.1.2. Others
15.6. Middle East & Africa Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Middle East & Africa Acute Exacerbation of CRS Treatment Market Attractiveness Analysis
15.7.1. By Treatment
15.7.2. By Route of Administration
15.7.3. By Distribution Channel
15.7.4. By Infection Type
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Position Analysis, by Company, 2020
16.2. Company Profiles
16.2.1. Sun Pharmaceutical Industries, Inc.
16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.1.2. Growth Strategies
16.2.1.3. SWOT Analysis
16.2.2. Pfizer Inc.
16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.2.2. Growth Strategies
16.2.2.3. SWOT Analysis
16.2.3. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.3.2. Growth Strategies
16.2.3.3. SWOT Analysis
16.2.4. Fresenius Kabi USA, LLC.
16.2.4.1. Company Overview (HQ, Business Segments)
16.2.4.2. Growth Strategies
16.2.4.3. SWOT Analysis
16.2.5. Dr. Reddy's Laboratories, Inc.
16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.5.2. Growth Strategies
16.2.5.3. SWOT Analysis
16.2.6. Novartis AG
16.2.6.1. Company Overview (HQ, Business Segments)
16.2.6.2. Growth Strategies
16.2.6.3. SWOT Analysis
16.2.7. Teva Pharmaceutical Industries Ltd
16.2.7.1. Company Overview (HQ, Business Segments)
16.2.7.2. Growth Strategies
16.2.7.3. SWOT Analysis
16.2.8. Sanofi
16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.8.2. Growth Strategies
16.2.8.3. SWOT Analysis
16.2.9. Abbott Laboratories
16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.9.2. Growth Strategies
16.2.9.3. SWOT Analysis
16.2.10. Bayer AG
16.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.10.2. Growth Strategies
16.2.10.3. SWOT Analysis
16.2.11. Eli Lilly And Company
16.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.11.2. Growth Strategies
16.2.11.3. SWOT Analysis
16.2.12. Bristol-Myers Squibb
16.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.12.2. Growth Strategies
16.2.12.3. SWOT Analysis
16.2.13. Merck & Co, Inc.
16.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.13.2. Growth Strategies
16.2.13.3. SWOT Analysis
16.2.14. AstraZeneca Plc
16.2.14.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.14.2. Growth Strategies
16.2.14.3. SWOT Analysis
16.2.15. Amneal Pharmaceuticals LLC
16.2.15.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.15.2. Growth Strategies
16.2.15.3. SWOT Analysis
16.2.16. GlaxoSmithKline plc.
16.2.16.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.16.2. Growth Strategies
16.2.16.3. SWOT Analysis
16.2.17. Aurobindo Pharma
16.2.17.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.17.2. Growth Strategies
16.2.17.3. SWOT Analysis
16.2.18. Hikma Pharmaceuticals plc
16.2.18.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.18.2. Growth Strategies
16.2.18.3. SWOT Analysis
16.2.19. Wockhardt
16.2.19.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.19.2. Growth Strategies
16.2.19.3. SWOT Analysis
16.2.20. Mylan N.V.
16.2.20.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.20.2. Growth Strategies
16.2.20.3. SWOT Analysis
List of Tables
Table 01: Global Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 02: Global Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031
Table 03: Global Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 04: Global Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 05: Global Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
Table 06: Global Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 07: North America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 08: North America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 09: North America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031
Table 10: North America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 11: North America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 12: North America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
Table 13: Europe Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Europe Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 15: Europe Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031
Table 16: Europe Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 17: Europe Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 18: Europe Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
Table 19: Asia Pacific Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 20: Asia Pacific Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 21: Asia Pacific Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031
Table 22: Asia Pacific Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 23: Asia Pacific Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 24: Asia Pacific Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
Table 25: Latin America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 26: Latin America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 27: Latin America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031
Table 28: Latin America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 29: Latin America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 30: Latin America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
Table 31: Middle East & Africa Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 32: Middle East & Africa Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 33: Middle East & Africa Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031
Table 34: Middle East & Africa Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 35: Middle East & Africa Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 36: Middle East & Africa Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
List of Figures
Figure 01: Global Acute Exacerbation of CRS Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Acute Exacerbation of CRS Market Attractiveness Analysis, by Treatment, 2021–2031
Figure 03: Global Acute Exacerbation of CRS Market Value Share Analysis, by Treatment, 2020 and 2031
Figure 04: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Antibiotics, 2017–2031
Figure 05: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Leukotriene Inhibitors, 2017–2031
Figure 06: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Antihistamines, 2017–2031
Figure 07: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Mucolytics, 2017–2031
Figure 08: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Decongestants, 2017–2031
Figure 09: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Nasal Saline Irrigation, 2017–2031
Figure 10: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Oral Corticosteroids, 2017–2031
Figure 11: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Endoscopic Sinus Surgery, 2017–2031
Figure 12: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Others, 2017–2031
Figure 13: Global Acute Exacerbation of CRS Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 14: Global Acute Exacerbation of CRS Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 15: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Topical, 2017–2031
Figure 16: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Nasal, 2017–2031
Figure 17: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Oral, 2017–2031
Figure 18: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Injectable, 2017–2031
Figure 19: Global Acute Exacerbation of CRS Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 20: Global Acute Exacerbation of CRS Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 21: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Online Pharmacies, 2017-2031
Figure 22: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Retail Pharmacies, 2017-2031
Figure 23: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Online Pharmacies, 2017-2031
Figure 24: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Retail Pharmacies, 2017-2031
Figure 25: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Hospital Pharmacies, 2017-2031
Figure 26: Global Acute Exacerbation of CRS Market Value Share Analysis, by Infection Type, 2020 and 2031
Figure 27: Global Acute Exacerbation of CRS Market Attractiveness Analysis, by Infection Type, 2021–2031
Figure 28: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Staphylococcus Species, 2017–2031
Figure 29: Global Acute Exacerbation of CRS Market Value (US$ Mn), by Others, 2017–2031
Figure 30: Global Acute Exacerbation of CRS Market Value Share Analysis, by Region, 2020 and 2031
Figure 31: Global Acute Exacerbation of CRS Market Attractiveness Analysis, by Region, 2021–2031
Figure 32: North America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 33: North America Acute Exacerbation of CRS Market Value Share, by Country, 2020 and 2031
Figure 34: North America Acute Exacerbation of CRS Market Attractiveness Analysis, by Country, 2021–2031
Figure 35: North America Acute Exacerbation of CRS Market Attractiveness Analysis, by Treatment, 2021–2031
Figure 36: North America Acute Exacerbation of CRS Market Value Share Analysis, by Treatment, 2020 and 2031
Figure 37: North America Acute Exacerbation of CRS Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 38: North America Acute Exacerbation of CRS Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 39: North America Acute Exacerbation of CRS Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 40: North America Acute Exacerbation of CRS Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 41: North America Acute Exacerbation of CRS Market Value Share Analysis, by Infection Type, 2020 and 2031
Figure 42: North America Acute Exacerbation of CRS Market Attractiveness Analysis, by Infection Type, 2021–2031
Figure 43: Europe Acute Exacerbation of CRS Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 44: Europe Acute Exacerbation of CRS Market Value Share, by Country/Sub-region, 2020 and 2031
Figure 45: Europe Acute Exacerbation of CRS Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 46: Europe Acute Exacerbation of CRS Market Attractiveness Analysis, by Treatment, 2021–2031
Figure 47: Europe Acute Exacerbation of CRS Market Value Share Analysis, by Treatment, 2020 and 2031
Figure 48: Europe Acute Exacerbation of CRS Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 49: Europe Acute Exacerbation of CRS Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 50: Europe Acute Exacerbation of CRS Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 51: Europe Acute Exacerbation of CRS Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 52: Europe Acute Exacerbation of CRS Market Value Share Analysis, by Infection Type, 2020 and 2031
Figure 53: Europe Acute Exacerbation of CRS Market Attractiveness Analysis, by Infection Type, 2021–2031
Figure 54: Asia Pacific Acute Exacerbation of CRS Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 55: Asia Pacific Acute Exacerbation of CRS Market Value Share, by Country/Sub-region, 2020 and 2031
Figure 56: Asia Pacific Acute Exacerbation of CRS Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 57: Asia Pacific Acute Exacerbation of CRS Market Attractiveness Analysis, by Treatment, 2021–2031
Figure 58: Asia Pacific Acute Exacerbation of CRS Market Value Share Analysis, by Treatment, 2020 and 2031
Figure 59: Asia Pacific Acute Exacerbation of CRS Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 60: Asia Pacific Acute Exacerbation of CRS Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 61: Asia Pacific Acute Exacerbation of CRS Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 62: Asia Pacific Acute Exacerbation of CRS Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 63: Asia Pacific Acute Exacerbation of CRS Market Value Share Analysis, by Infection Type, 2020 and 2031
Figure 64: Asia Pacific Acute Exacerbation of CRS Market Attractiveness Analysis, by Infection Type, 2021–2031
Figure 65: Latin America Acute Exacerbation of CRS Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 66: Latin America Acute Exacerbation of CRS Market Value Share, by Country/Sub-region, 2020 and 2031
Figure 67: Latin America Acute Exacerbation of CRS Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 68: Latin America Acute Exacerbation of CRS Market Attractiveness Analysis, by Treatment, 2021–2031
Figure 69: Latin America Acute Exacerbation of CRS Market Value Share Analysis, by Treatment, 2020 and 2031
Figure 70: Latin America Acute Exacerbation of CRS Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 71: Latin America Acute Exacerbation of CRS Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 72: Latin America Acute Exacerbation of CRS Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 73: Latin America Acute Exacerbation of CRS Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 74: Latin America Acute Exacerbation of CRS Market Value Share Analysis, by Infection Type, 2020 and 2031
Figure 75: Latin America Acute Exacerbation of CRS Market Attractiveness Analysis, by Infection Type, 2021–2031
Figure 76: Middle East & Africa Acute Exacerbation of CRS Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 77: Middle East & Africa Acute Exacerbation of CRS Market Value Share, by Country/Sub-region, 2020 and 2031
Figure 78: Middle East & Africa Acute Exacerbation of CRS Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 79: Middle East & Africa Acute Exacerbation of CRS Market Attractiveness Analysis, by Treatment, 2021–2031
Figure 80: Middle East & Africa Acute Exacerbation of CRS Market Value Share Analysis, by Treatment, 2020 and 2031
Figure 81: Middle East & Africa Acute Exacerbation of CRS Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 82: Middle East & Africa Acute Exacerbation of CRS Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 83: Middle East & Africa Acute Exacerbation of CRS Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 84: Middle East & Africa Acute Exacerbation of CRS Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 85: Middle East & Africa Acute Exacerbation of CRS Market Value Share Analysis, by Infection Type, 2020 and 2031
Figure 86: Middle East & Africa Acute Exacerbation of CRS Market Attractiveness Analysis, by Infection Type, 2021–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Acute Exacerbation of CRS Treatment Market Outlook, 2021-2031
*86 figures and 60 tables includes